Compare Quest Diagnostics Inc (DGX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: Quest Diagnostics Inc is far larger — about 45.5× Direxion Daily FTSE China Bull 3x Shares's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| DGX | YINN | |
|---|---|---|
Market Cap | $25.48B | $560.32M |
Volume | 941,866 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $52.69 |
52-Week Low | $173.49 | $21.45 |
Typical Hold Time | 56 Days | 25 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
YINN trades at $23.63, up 0.3% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. Moving averages indicate strong bearish momentum while oscillators remain neutral. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific fundamentals show limited available data.
The bearish technical setup and lack of clear fundamental metrics create uncertainty. Investment opportunity depends on broader market trends and China's economic developments, while risks include technical breakdown below support and regional economic volatility. Further fundamental disclosure is needed for comprehensive analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
